German drugmaker Schering has entered into a deal with AstraZeneca to jointly develop a new breast cancer drug.
The drug that the two companies plan to jointly develop, which Schering currently is putting through pre-clinical trials, is a SERD, or selective oestrogen receptor downregulator. SERDs are a new class of compounds which work by breaking down resistance to hormone-oriented treatments for breast cancer.
The deal marks the latest step by AstraZeneca to rebuild its pipeline following past high-profile setbacks, including the failure in clinical trials of anti-coagulant Exanta, Iressa for lung cancer and diabetes drug Galida.
More from Reuters
Insider's view: First Abbott with cholesterol combos now Schering (Bayer) for breast cancer. Looks suspiciously like AZ are "snuggling up" to a few friends in the industry to see what develops!
No comments:
Post a Comment